Trial Profile
Phase Ib/II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Jan 2023 Status changed from active, no longer recruiting to completed.
- 28 Feb 2021 Planned End Date changed from 30 Dec 2020 to 1 Apr 2021.
- 31 Aug 2020 Planned primary completion date changed from 30 Jun 2020 to 30 Oct 2020.